Quick Answer
Aurinia Pharmaceuticals Inc. reported Stockholders Equity of $581.33 million for the year ending 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +54.0% in Stockholders Equity from 2024 to 2025.
- This data is from Aurinia Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $279.09 million | Q2 2020: $257.70 million | Q3 2020: $409.44 million | Q1 2021: $370.23 million | Q2 2021: $332.26 million | Q3 2021: $298.17 million | Q1 2022: $448.12 million | Q2 2022: $423.77 million | Q3 2022: $423.43 million | Q1 2023: $390.41 million | Q2 2023: $392.29 million | Q3 2023: $391.88 million | Q1 2024: $359.48 million | Q2 2024: $364.62 million | Q3 2024: $388.00 million | Q1 2025: $350.19 million | Q2 2025: $335.30 million | Q3 2025: $365.77 million.
- Over the full 9 years of available data (2017 to 2025), Aurinia Pharmaceuticals Inc.'s Stockholders Equity has grown by 226.7%.
- Historical annual values: Fiscal year 2025: $581.33 million | Fiscal year 2024: $377.48 million | Fiscal year 2023: $377.95 million | Fiscal year 2022: $405.44 million | Fiscal year 2021: $479.09 million | Fiscal year 2020: $407.75 million | Fiscal year 2019: $298.60 million | Fiscal year 2018: $135.72 million | Fiscal year 2017: $177.92 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: